6-K

ERYTECH Pharma S.A.

Date: June 26, 2020

/s/ Eric Soyer

Eric Soyer

Chief Financial Officer and Chief Operating Officer

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of June 2020

Commission File Number: 001-38281

ERYTECH Pharma S.A.

(Translation of registrant’s name into English)

60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Press Release

On June 26, 2020, Erytech Pharma S.A. (the “Company”) issued a press release announcing the voting results of its Annual General Meeting held on June 26, 2020. A copy of the press release is attached to this Report on Form 6-K as Exhibit 99.1.

EXHIBITS


Exhibit		Description

99.1		Press Release dated June 26, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Exhibit 99.1


		PRESS RELEASE

ERYTECH Reports Voting Results from its Annual General Meeting Held on June 26, 2020

Lyon (France) and Cambridge (U.S.), June 26, 2020 – ERYTECH Pharma (Euronext: ERYP—Nasdaq: ERYP) announced that its 2020 Annual General Meeting was held in Lyon on Friday, June 26, 2020.

At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including:

-	Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2019;

-	Allocation of the financial year’s results;

-	Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;

-	Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2019 to Gil BEYEN and Jean-Paul KRESS;

-	Approval of the compensation policy for executive corporate officers and board members;

-	Renewal of the term of office as Director of:

HILDE WINDELS BV

Martine GEORGE

-	Ratification of the appointment by cooptation of Melanie ROLLI as Director;

-	Approval of the share subscription and/or purchase options plan adopted by the Board of Directors on July 31, 2019;

-	Delegations of authority to the Board of Directors to issue shares or other marketable securities convertible into shares to be issued immediately or in the future by the Company, with or without preferential subscription rights for the shareholders;

-	Authorization for the Board of Directors to grant free shares, share subscription and/or share purchase options and/or to issue share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma Group.

The full results of all matters voted on at the meeting can be viewed on the Company’s website at www.erytech.com, within the Shareholders Meeting/2020 section under the Investors tab.

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS^® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.For more information, please visit www.erytech.com

CONTACTS


ERYTECH Eric Soyer CFO & COO	LifeSci Advisors, LLC Investor Relations Corey Davis, Ph.D.	NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations Nicolas Merigeau Media relations

+33 4 78 74 44 38 investors@ERYTECH.com	+1 (212) 915—2577 cdavis@lifesciadvisors.com	+33 1 44 71 94 94 ERYTECH@newcap.eu